SanofiSNY
SNY
About: Sanofi develops and markets drugs with a concentration in vaccines, immunology, oncology, cardiovascular disease, diabetes, and over-the-counter treatments. However, the company's decision in late 2019 to pull back from the cardio-metabolic area will likely reduce the firm's footprint in this large therapeutic area. The company offers a diverse array of drugs with its highest revenue generator, Dupixent, representing about 30% of total sales, but profits are shared with Regeneron. Just over 40% of total revenue comes from the United States and 25% from Europe. Emerging markets represent the majority of the remainder of revenue.
Employees: 82,878
0
Funds holding %
of 7,419 funds
–
Analysts bullish %
Fund manager confidence
Based on 2024 Q4 regulatory disclosures by fund managers ($100M+ AUM)
27% more call options, than puts
Call options by funds: $94.5M | Put options by funds: $74.6M
1.3% less ownership
Funds ownership: 22.21% [Q3] → 20.9% (-1.3%) [Q4]
4% less funds holding
Funds holding: 742 [Q3] → 710 (-32) [Q4]
13% less repeat investments, than reductions
Existing positions increased: 244 | Existing positions reduced: 279
15% less funds holding in top 10
Funds holding in top 10: 13 [Q3] → 11 (-2) [Q4]
16% less first-time investments, than exits
New positions opened: 76 | Existing positions closed: 90
21% less capital invested
Capital invested by funds: $16.2B [Q3] → $12.8B (-$3.49B) [Q4]
Research analyst outlook
1 Wall Street Analyst provided 1 year price targets over the past 3 months
Low target
$65
23%
upside
Avg. target
$65
23%
upside
High target
$65
23%
upside
1 analyst rating
0 positive
0%
1 neutral
100%
0 negative
0%
Goldman Sachs James Quigley 0 / 0 met price target | 23%upside $65 | Neutral Initiated | 21 Mar 2025 |
Financial journalist opinion
Based on 29 articles about SNY published over the past 30 days
Positive
WSJ
2 hours ago
Sanofi Sales, Profit Beat Expectations on Higher Demand for Skin, Asthma Drug
The pharmaceutical company said the profit was driven by a higher gross margin and slower operating expense growth.
Positive
Reuters
5 hours ago
Sanofi's quarterly profit beats estimates on Dupixent boost, newer products
France's Sanofi reported first-quarter profit that beat analysts' expectations on Thursday, boosted by strong demand for its anti-inflammatory drug Dupixent, as well as newer treatments and vaccines.
Neutral
GlobeNewsWire
5 hours ago
Press Release: Sanofi: strong Q1 performance and 2025 guidance confirmed
Sanofi: strong Q1 performance and 2025 guidance confirmed Paris, April 24, 2025 Q1 sales growth of 9.7% at CER 1 and business EPS 2 of €1.79 Pharma launches reached sales of €0.8 billion, up 43.8%, driven by ALTUVIIIO Dupixent sales were €3.5 billion, up 20.3% Vaccines sales were €1.3 billion, up 11.4%, driven by favorable Beyfortus phasing Research and Development expenses reached €1.8 billion, up 6.9% Selling, general and administrative expenses were €2.2 billion, up 3.8% Business EPS was €1.79, up 15.7% at CER and up 17.0% reported; IFRS EPS was €1.52 Pipeline continued to deliver Six regulatory approvals across medicines in immunology, rare diseases, and oncology Recent new data from the mid-stage pipeline unlocks late-stage studies in asthma and skin diseases, broadening and deepening the scope in immunology Sustainability strategy Updated sustainability strategy focuses on access to healthcare, environmental impact, and resilience of healthcare systems. 70% of the portfolio and >75% of the pipeline target diseases that are impacted by climate and environmental challenges Capital allocation The closing of the sale of a controlling stake in Opella to CD&R is anticipated in Q23 Sanofi has agreed to acquire DR-0201, a targeted bispecific myeloid cell engager4 Guidance confirmed In 2025, sales are anticipated to grow by a mid-to-high single-digit percentage at CER5.
Neutral
Reuters
1 day ago
Novartis and Sanofi CEOs say EU should raise drug prices in face of tariffs
The European Union should allow drug prices to rise to U.S. levels in order to attract investment, the bosses of two European pharmaceutical giants said in a letter published in the Financial Times on Wednesday.
Positive
Zacks Investment Research
1 day ago
Will These 5 Large Drug Maker Stocks Surpass Q1 Earnings Forecast?
Let's look at five big pharma companies, GILD, BMY, MRK, ABBV and SNY slated to release their first-quarter 2025 results this week.
Positive
Zacks Investment Research
2 days ago
Sanofi & Regeneron's Dupixent Receives FDA Nod for Urticaria
The FDA approves SNY and REGN's Dupixent for treating chronic spontaneous urticaria, marking the seventh approved indication of the drug.
Positive
Reuters
5 days ago
Sanofi-Regeneron's Dupixent gets FDA's nod for skin condition
The U.S. Food and Drug Administration approved the extended use of Sanofi and Regeneron's blockbuster drug Dupixent for patients with a type of skin condition, the two companies said on Friday.
Neutral
GlobeNewsWire
5 days ago
Press Release: Dupixent approved in the US as the first new targeted therapy in over a decade for chronic spontaneous urticaria
Dupixent approved in the US as the first new targeted therapy in over a decade for chronic spontaneous urticaria Approval based on phase 3 studies demonstrating Dupixent significantly reduced itch and hives compared to placebo In the US, there are more than 300,000 adults and adolescents aged 12 years and older living with CSU who remain symptomatic despite antihistamine treatment CSU is the seventh disease with underlying type 2 inflammation in which Dupixent is approved Paris and Tarrytown, NY, April 18, 2025. The US Food and Drug Administration (FDA) has approved Dupixent (dupilumab) for the treatment of adults and adolescents aged 12 years and older with chronic spontaneous urticaria (CSU) who remain symptomatic despite histamine-1 (H1) antihistamine treatment.
Neutral
Zacks Investment Research
1 week ago
Sanofi Advances Mid-to-Late-Stage Pipeline in Respiratory Indications
SNY shares preliminary data from phase II study on amlitelimab in moderate-to-severe asthma. It also provides updates on lunsekimig and itepekimab studies.
Neutral
GlobeNewsWire
1 week ago
Press Release: Sanofi's respiratory pipeline advances with new data in asthma and plans for new clinical studies in COPD
Sanofi's respiratory pipeline advances with new data in asthma and plans for new clinical studies in COPD New phase 2 data for amlitelimab show efficacy in heterogeneous inflammatory asthma Lunsekimig now targeting chronic rhinosinusitis and COPD in addition to asthma Itepekimab expanding into chronic rhinosinusitis along with COPD and bronchiectasis; phase 3 readouts in COPD in H2 2025 and bronchiectasis in 2026 Paris, April 15, 2025. Sanofi today shared new progress from its mid- to late-stage respiratory pipeline, including preliminary phase 2 results for amlitelimab in adults with moderate-to-severe asthma.
Charts implemented using Lightweight Charts™